跳转至内容

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新,请点击此处查看详情。

Merck
CN

In-vitro activity of avermectins against Mycobacterium ulcerans.

PLoS neglected tropical diseases (2015-03-06)
Till F Omansen, Jessica L Porter, Paul D R Johnson, Tjip S van der Werf, Ymkje Stienstra, Timothy P Stinear
摘要

Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU.

材料
货号
品牌
产品描述

Sigma-Aldrich
利福平, ≥95% (HPLC), powder or crystals
登录查看公司和协议定价
货号包装规格是否有货价格数量
60 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥1,096.69
Supelco
莫昔克丁, VETRANAL®, analytical standard
登录查看公司和协议定价
货号包装规格是否有货价格数量
60 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥1,096.69
莫昔克丁, European Pharmacopoeia (EP) Reference Standard
登录查看公司和协议定价
货号包装规格是否有货价格数量
60 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥1,096.69